Cancer

Explore the complexities of Cancer research and treatment in China’s pharmaceutical industry. At Fineline Info & Tech, we provide reliable data, news, and insights to enhance your understanding and decision-making. Stay informed and stay ahead in the fight against cancer with flcube.com.

Minghui Pharmaceutical Strikes Exclusive Japan License Deal with ASKA for MHB018A – $110 Million Upfront, Up to $330 Million in Milestones and Mid‑30 % Royalties for Thyroid Eye Disease Antibody
CompanyDeals

Minghui Pharmaceutical Strikes Exclusive Japan License Deal with ASKA for MHB018A – $110 Million Upfront, Up to $330 Million in Milestones and Mid‑30 % Royalties for Thyroid Eye Disease Antibody

Minghui Pharmaceutical and ASKA Pharmaceutical Co., Ltd. jointly announced an exclusive licensing agreement for the development and commercialization of MHB018A in Japan. Under the terms, Minghui Pharmaceutical will receive an…

Pfizer Raises Full‑Year 2026 Guidance as Q3 Revenue Holds Flat at $16.6 Billion – Launched and Acquired Products Surge 32%, Cecile Guegan Named CFO

Pfizer Raises Full‑Year 2026 Guidance as Q3 Revenue Holds Flat at $16.6 Billion – Launched and Acquired Products Surge 32%, Cecile Guegan Named CFO

CStone Pharmaceuticals Partners with Kimia Therapeutics to Co‑Develop Potential First‑in‑Class DDR Inhibitor for Solid Tumors – CStone to Lead Phase I in Mainland China and Australia

CStone Pharmaceuticals Partners with Kimia Therapeutics to Co‑Develop Potential First‑in‑Class DDR Inhibitor for Solid Tumors – CStone to Lead Phase I in Mainland China and Australia

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Hengrui’s HER2-Targeted ADC SHR-A1811 Aims for Breakthrough Designation

CompanyDrug

EOC Pharma’s CDK7 Inhibitor EOC237 Accepted for CDE Review

CompanyDeals

Nona Biosciences Partners with Mythic Therapeutics for Next-Gen ADCs

CompanyDrug

Hinova’s HP530S Accepted for NMPA Review as FAK Inhibitor for Solid Tumors

CompanyDrug

Qilu Pharmaceutical’s QLS12004 Gains Tacit Clinical Trial Approval

CompanyDrug

ImmVira’s MVR-T3011 IT Shows Efficacy in Melanoma Treatment

CompanyDeals

Hemay Pharma Completes Series D Financing for Autoimmune and Oncology Drugs

CompanyDrug

SciClone Pharmaceuticals Files for Hong Kong Market Approval of Danyelza

Show More